Precision Nanosystems NanoAssemblr Ignite

Description

The Precision Nanosystems NanoAssemblr Ignite provides precise and controlled formulation of lipid nanoparticles (LNPs) using advanced NxGen mixing technology, making it a vital tool in the development of preclinical genomic medicine. By maintaining consistent process parameters with the NanoAssemblr Blaze and GMP System, the Ignite streamlines the transition to clinical development and manufacturing, ensuring effortless formulation scaling. This approach combines crucial process steps for scale-up during preclinical development, even at minimal volumes. This aids in reducing risks, simplifying workflows, and accelerating drug development timelines. The NxGen technology minimises batch-to-batch and user variability, provides accurate control over fluidic flow rates and ratios, and enables fine-tuning of critical quality attributes (CQAs) such as particle size.

The Nanosystem’s single-use design ensures sterile and efficient processing while providing precise control over fluidic flow rates and ratios. In terms of applications, the NanoAssemblr Ignite enables researchers to conduct both in vitro and in vivo screens as well as proof-of-concept studies. It assesses the potency and toxicity of excipients and characterises the physico-chemical properties of formulations. Researchers can also test formulations in relevant biological models and profile pharmacokinetics, biodynamics, efficacy, and toxicity within disease models. The Ignite supports the identification of lead candidates for scale-up and process development, optimises lead formulations, selects excipients for formulation development, and models clinically relevant parameters and processes at small volumes.

Key Features of the Precision Nanosystems NanoAssemblr Ignite:

Maximum Volume 20 mL
Maximum Flow Rate 20 mL/min
NxGen Microfluidic Mixing Technology
- Scalable Formulations Across NanoAssemblr Platform
- Minimises Batch-to-Batch and User Variability
- Single-Use Technology
Precise Control Over Fluidic Flow Rates & Ratios
- Fine Tune Critical Quality Attributes (CQAs) e.g. Particle Size
Perform in vitro or in vivo Screens and Proof of Concept
Determine Potency and Toxicity of Excipients
Characterise Physico-Chemical Properties
- Test in Relevant Biological Models
Profile PK, Biodynamics, Efficacy and Toxicity in Disease Model
Select Lead Candidate(s) for Scale-Up Process Development
Select Lead Formulations for Further Optimisation
Select Excipients for Formulation Development
Model Clinically Relevant Parameters and Processes at Small Volumes
Model: NIN0001